| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 10,365 | 9,557 |
| Pretax Income | 4,686 | 3,921 |
| Net Income | 3,864 | 3,216 |
| Diluted EPS | 7.08 | 5.93 |
- Net Income YoY
- +20.1%
Key highlights
- Total revenues reached $10,365 million, an 8.4% increase from $9,557 million in Q3 2025
- Net income rose 20.1% year-over-year to $3,864 million
- Diluted earnings per share (EPS) grew to $7.08 from $5.93 in the prior year
- Pretax income for the quarter climbed to $4,686 million, up from $3,921 million
- Management reaffirmed full-year 2026 revenue guidance of $38,900 million to $39,700 million
How the Period Went
Amgen Inc. reported total revenues of $10,365 million for the third quarter of 2026, representing an 8.4% increase compared to the $9,557 million recorded in the same period last year. This top-line expansion was primarily supported by growth in product sales across the company's core biopharmaceutical portfolio. The bottom line saw a more pronounced uplift, with net income rising 20.1% to $3,864 million, compared to $3,216 million in the prior year. Consequently, diluted earnings per share increased to $7.08 from $5.93. The disparity between revenue and income growth suggests significant contributions from non-operating items and effective management of operational expenses during the three-month period.
Margins and Profitability
Pretax income for the quarter reached $4,686 million, up from $3,921 million in the third quarter of 2025. This growth in profitability was bolstered by higher operating income and gains categorized under other income. While the core biopharmaceutical operations remained the primary profit driver, these non-operating gains played a material role in the 20.1% year-over-year increase in net income. The firm’s ability to scale its earnings ahead of its revenue growth reflects a period of heightened operational efficiency, even as it continues to fund an extensive research and development pipeline for future biologic drug candidates.
Business Overview
Amgen is a global biotechnology leader focused on developing therapies for serious illnesses in areas including oncology, inflammation, bone health, and cardiovascular disease. The company operates within the general drug manufacturing industry, leveraging sophisticated molecular biology to produce complex medicines. Amgen manages a diverse portfolio of established brands and biosimilars, serving healthcare providers and patients worldwide. The third quarter results underscore the company’s focus on maximizing the commercial value of its existing product lineup while transitioning toward high-potential late-stage clinical assets, such as its ongoing work in obesity and autoimmune therapeutic areas.
Financial Context and Guidance
- Full-year 2026 total revenue guidance is set between $38,900 million and $39,700 million (source: amgen.com)
- The company announced a fourth-quarter 2026 cash dividend of $2.52 per share payable on December 11, 2026
- Amgen's market capitalization stands at $249,371.9 million with a P/E ratio of 28.65x
- Stock price momentum is significant, with a 20.46% gain over the last three months and a 14.45% gain over the last month
- The 14-day Relative Strength Index (RSI) of 67.2 indicates the stock is nearing a technically overbought territory
Up 0.2% since our story on 4 Nov: $461.26 when we broke it → $462.32 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $424.94 |
|---|---|
| 20 Oct | $438.94 |
| 21 Oct | $438.34 |
| 22 Oct | $447.28 |
| 23 Oct | $439.26 |
| 26 Oct | $444.63 |
| 27 Oct | $447.95 |
| 28 Oct | $451.83 |
| 29 Oct | $460.73 |
| 30 Oct | $466.01 |
| 2 Nov | $465.45 |
| 3 Nov | $461.26 |
| 4 Nov | $478.48 |
| 5 Nov | $460.28 |
| 6 Nov | $460.42 |
| 9 Nov | $465.23 |
| 10 Nov | $465.23 |
| 11 Nov | $468.11 |
| 12 Nov | $467.06 |
| 13 Nov | $465.67 |
| 16 Nov | $462.32 |
Industry Landscape
The biopharmaceutical sector is navigating a landscape defined by high demand for specialty medicines and strategic expansion into metabolic disease treatments. Amgen’s 8.4% revenue growth occurs as peers like Gilead Sciences and AbbVie also focus on oncology and inflammation therapies to diversify revenue streams. The industry is closely monitoring the development of obesity treatments, a space where Amgen remains active. A significant upcoming milestone for the company includes the topline Phase 3 clinical data readout for dazodalibep in symptomatic Sjögren's disease, expected in the fourth quarter of 2026 (source: investors.amgen.com). This clinical progress is central to maintaining competitiveness in the pharmaceutical landscape.
| Date | Announcement | Amount |
|---|---|---|
| 03 Nov 2026 | Q3 2026 total revenues and FY 2026 guidance updateSource: amgen.com | $10.40 Billion |
| 04 Aug 2026 | Q2 2026 total revenues and FY 2026 guidance updateSource: amgen.com | $10.10 Billion |
| 30 Apr 2026 | Q1 2026 total revenues and FY 2026 guidance updateSource: prnewswire.com | $8.60 Billion |
| 03 Feb 2026 | Q4 2025 total revenues and FY 2026 guidanceSource: amgen.com | $9.90 Billion |
| 04 Nov 2025 | Q3 2025 total revenues and FY 2025 guidance updateSource: amgen.com | $9.60 Billion |
| 05 Aug 2025 | Q2 2025 total revenues and FY 2025 guidance updateSource: amgen.com | $9.20 Billion |
| Share price | $461.26 |
|---|---|
| Market cap | $249.4B |
| Revenue (annual) | $36.8B |
| P/E (TTM) | 28.6× |
| 1-month price change | +14.45% |
| Sector | HealthcareDrug Manufacturers - General |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Amgen Inc. announcing third quarter 2026 financial results.
Track AMGEN INC live
Get the next AMGEN INC SEC filing seconds after it lands.



